Stoke Therapeutics (STOK) Receivables (2024 - 2026)

Stoke Therapeutics' Receivables history runs 3 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Receivables changed N/A year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (changed N/A YoY), while the FY2025 annual figure was $7.9 million, up 233.83% from the prior year.
• Receivables for Q1 2026 stood at $6.1 million, down from $7.9 million in the prior quarter.
• The five-year high for Receivables was $10.8 million in Q3 2025, with the low at $2.4 million in Q4 2024.
• The 3-year median for Receivables is $7.0 million (2025), against an average of $6.8 million.
• Peak annual rise in Receivables reached 233.83% in 2025, while the deepest fall reached 233.83% in 2025.
• Stoke Therapeutics' Receivables stood at $2.4 million in 2024, then soared by 233.83% to $7.9 million in 2025, then slipped by 22.31% to $6.1 million in 2026.
• Business Quant data shows STOK's Receivables at $6.1 million in Q1 2026, $7.9 million in Q4 2025, and $10.8 million in Q3 2025.